Page last updated: 2024-12-08
sporothriolide
Description
sporothriolide: a furofurandione; from Sporothrix sp.; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
sporothriolide : A furofuran that is (3aR,6aR)-hexahydrofuro[3,4-b]furan substituted by an oxo group at positions 2 and 4, methylene group at position 3 and by an hexyl group at position 6. It is a metabolite isolated from several species of fungi. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (6)
Synonym |
sporothriolide |
CHEBI:141338 |
furo[3,4-b]furan-2,4-dione,6-hexyltetrahydro-3-methylene-, (3as,6r,6ar)- |
(3as,6r,6ar)-6-hexyl-3-methylenetetrahydrofuro[3,4-b]furan-2,4-dione |
CHEMBL4175317 |
(3as,6r,6ar)-6-hexyl-3-methylidene-6,6a-dihydro-3ah-furo[3,4-b]furan-2,4-dione |
Roles (2)
Role | Description |
antifungal agent | An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. |
fungal metabolite | Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
gamma-lactone | A lactone having a five-membered lactone ring. |
furofuran | Organic heterobicyclic compounds containing a two furan rings ortho-fused to each other. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (6)
Assay ID | Title | Year | Journal | Article |
AID1503769 | Antibacterial activity against Escherichia coli | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. |
AID1503771 | Antibacterial activity against Micrococcus luteus | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. |
AID1503770 | Antibacterial activity against Bacillus subtilis | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. |
AID1503767 | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. |
AID1503768 | Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. |
AID1503772 | Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay | 2017 | Journal of natural products, 10-27, Volume: 80, Issue:10
| Sporothriolide-Related Compounds from the Fungus Hypoxylon monticulosum CLL-205 Isolated from a Sphaerocladina Sponge from the Tahiti Coast. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (14.29) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 3 (42.86) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |